JP2007509057A5 - - Google Patents

Download PDF

Info

Publication number
JP2007509057A5
JP2007509057A5 JP2006535366A JP2006535366A JP2007509057A5 JP 2007509057 A5 JP2007509057 A5 JP 2007509057A5 JP 2006535366 A JP2006535366 A JP 2006535366A JP 2006535366 A JP2006535366 A JP 2006535366A JP 2007509057 A5 JP2007509057 A5 JP 2007509057A5
Authority
JP
Japan
Prior art keywords
alkyl
composition
optionally substituted
halogen
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006535366A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007509057A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/034169 external-priority patent/WO2005037791A1/en
Publication of JP2007509057A publication Critical patent/JP2007509057A/ja
Publication of JP2007509057A5 publication Critical patent/JP2007509057A5/ja
Pending legal-status Critical Current

Links

JP2006535366A 2003-10-15 2004-10-15 ウイルス阻害のための組成物および方法 Pending JP2007509057A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51176903P 2003-10-15 2003-10-15
PCT/US2004/034169 WO2005037791A1 (en) 2003-10-15 2004-10-15 Compositions and methods for viral inhibition

Publications (2)

Publication Number Publication Date
JP2007509057A JP2007509057A (ja) 2007-04-12
JP2007509057A5 true JP2007509057A5 (enExample) 2007-11-22

Family

ID=34465275

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006535366A Pending JP2007509057A (ja) 2003-10-15 2004-10-15 ウイルス阻害のための組成物および方法

Country Status (4)

Country Link
US (1) US20070276009A1 (enExample)
EP (1) EP1678137A1 (enExample)
JP (1) JP2007509057A (enExample)
WO (1) WO2005037791A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1980672B (zh) 2004-03-15 2011-05-04 Ptc医疗公司 用于抑制血管生成的咔啉衍生物
US7767689B2 (en) 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
US8076353B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
WO2006012310A2 (en) * 2004-06-25 2006-02-02 Genzyme Corporation Carbazole derivatives for treating polycystic kidney disease
US20090156621A1 (en) * 2004-11-22 2009-06-18 Kristian Gudmundsson Hcv inhibitors
US20090170906A1 (en) * 2004-11-22 2009-07-02 Kristjan Gudmundsson Hcv inhibitors
US20090170923A1 (en) * 2004-11-22 2009-07-02 Kristjan Gudmundsson Hcv inhibitors
CA2588607A1 (en) 2004-11-23 2006-06-01 Ptc Therapeutics, Inc. Carbazole, carboline and indole derivatives useful in the inhibition of vegf production
JPWO2006085685A1 (ja) * 2005-02-09 2008-06-26 武田薬品工業株式会社 ピラゾール化合物
US7601856B2 (en) 2006-07-27 2009-10-13 Wyeth Benzofurans as potassium ion channel modulators
JP5526339B2 (ja) * 2007-10-26 2014-06-18 国立大学法人 鹿児島大学 複素芳香族化合物を有効成分とする抗ウイルス剤
WO2009103022A1 (en) * 2008-02-13 2009-08-20 Itherx Pharmaceuticals, Inc. Derivatives of substituted fused ring cycloindoles and methods of their use
WO2009114725A2 (en) 2008-03-12 2009-09-17 Children's Hospital Medical Center Mobilization of hematopoietic stem cells
RU2436786C1 (ru) * 2010-07-23 2011-12-20 Александр Васильевич Иващенко Замещенные индолы, противовирусный активный компонент, способ получения и применения
CA2873898A1 (en) * 2011-08-24 2013-02-28 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
WO2013139929A1 (en) * 2012-03-22 2013-09-26 Ludwig-Maximilians-Universität München Novel means and methods for treating diseases of the central nervous system, metabolic and cardiac diseases and aging
US10028503B2 (en) 2014-06-18 2018-07-24 Children's Hospital Medical Center Platelet storage methods and compositions for same
US11529354B2 (en) 2017-09-05 2022-12-20 President And Fellows Of Harvard College Methods and compositions for the treatment of tuberculosis
US10882821B1 (en) 2017-09-26 2021-01-05 The Board Of Trustees Of The Leland Stanford Junior University Enantiomeric compound for the reduction of the deleterious activity of extended nucleotide repeat containing genes
JP2022516030A (ja) * 2018-12-18 2022-02-24 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 遺伝子を含む伸長ヌクレオチドリピートの有害活性を低下させるための化合物
CN112094223B (zh) * 2019-06-18 2023-09-15 华东师范大学 一类脲基四氢咔唑类小分子有机化合物及用途
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors
US20240285598A1 (en) * 2021-05-28 2024-08-29 Arun K. Ghosh Compounds for the treatment of sars
CN117281120A (zh) * 2023-10-12 2023-12-26 兰州大学 一种四氢咔唑衍生物在防治农业细菌病害上的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994027607A1 (fr) * 1993-05-28 1994-12-08 Seikagaku Corporation Agent antiviral
JPH07188017A (ja) * 1993-09-30 1995-07-25 Souyaku Gijutsu Kenkyusho:Kk チアジアゾール誘導体を含有する抗ウイルス剤
JPH07126282A (ja) * 1993-11-01 1995-05-16 Nippon Kayaku Co Ltd 新規なチオヌクレオシド誘導体
US6037348A (en) * 1996-02-09 2000-03-14 Eli Lilly And Company Inhibition of viral replication
DE60001218D1 (de) * 1999-02-22 2003-02-20 Shire Biochem Inc [1,8]-naphthyridinderivate derivate mit antiviraler wirkung
AU4599601A (en) * 2000-01-07 2001-07-16 Eli Lilly And Company Substituted tricyclics
EP1248777A2 (en) * 2000-01-07 2002-10-16 Warner-Lambert Company Tricyclic compounds with antiviral activity
US20020107262A1 (en) * 2000-12-08 2002-08-08 3M Innovative Properties Company Substituted imidazopyridines
WO2005005386A1 (en) * 2003-06-12 2005-01-20 Smithkline Beecham Corporation Tetrahydrocarbazole derivatives and their pharmaceutical use
EP1658068B1 (en) * 2003-08-26 2009-02-18 Smithkline Beecham Corporation Novel cycloalkyl[b] condensed indoles

Similar Documents

Publication Publication Date Title
JP2007509057A5 (enExample)
RU2005106846A (ru) Производные бензотиазола, характеризующиеся агонистической активностью к бета-2-адренорецепторам
RU2395500C2 (ru) 2,4-пиримидиндиамины, применяемые в лечении неопластических болезней, воспалительных и иммунных расстройств
RU2002123350A (ru) Дипептиднитрильные ингибиторы катепсина К
JP2004513881A5 (enExample)
EA200600225A1 (ru) Производные пиперазина для лечения вич инфекций
NO20056007L (no) Dobbel NK1/NK3 antagonister for behandling av schizofreni
JP2005504042A5 (enExample)
JP2008504266A5 (enExample)
JP2006515858A5 (enExample)
RU2009148673A (ru) Производные пиразинона и их применение для лечения легочных заболеваний
RU2000126474A (ru) Производные индола, обладающие антивирусной активностью
JP2005539088A5 (enExample)
RU95118133A (ru) Гетероциклические соединения, способы их получения и фармацевтическая композиция
SE0104332D0 (sv) Therapeutic agents
CA2494832A1 (en) Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
IT1228293B (it) Benzoderivati di composti eterociclici contenenti azoto.
RU2009118254A (ru) Фенилацетамиды в качестве ингибиторов протеинкиназ
CA2281426A1 (en) Substituted indole compounds as anti-inflammatory and analgesic agents
RU97103983A (ru) Лекарственные композиции и производные триазина
JP2010527985A5 (enExample)
RU2004119963A (ru) Ингибиторы вич интегразы
JP2004525183A5 (enExample)
JP2005527521A5 (enExample)
DE602004023185D1 (de) Phenylsulfonderivate und deren verwendung bei der behandlung von zns-erkrankungen